Gilead’s rep takes another punishing blow as a bad, no good, awful year just got worse
Round two in the heavyweight fight over control of billions of dollars in hepatitis C drug money goes to Merck after a jury leveled a knockout, $2.54 billion punch against Gilead for violating its drug patents.
The record patent judgment covers a 10% royalty payment on Gilead’s blockbuster sales for Sovaldi and Harvoni, with the jury adding insult to injury by upholding Merck’s patent claims, which originated from its $3.9 billion buyout of Idenix in 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
